Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		$ 532.6	$ 438.0	$ 1,458.5	$ 1,315.9
Segment EBITDA		93.8	70.3	241.7	239.9
Inter-segment revenue elimination		(9.4)	(9.1)	(29.1)	(28.5)
Unallocated Costs	[1]	(32.8)	(17.1)	(72.9)	(43.9)
Impairment Charges And Gain Loss On Sale Of Assets		(1.8)	0.3	(2.3)	(0.8)
Equity compensation		(4.6)	(3.6)	(16.4)	(8.7)
Restructuring and other special items	[2]	(8.5)	(9.5)	(21.6)	(15.7)
Noncontrolling interest		0.0	0.0	0.0	0.3
Other income (expense), net	[3]	(7.3)	4.2	(3.4)	7.1
Non-allocated corporate costs, net		(10.6)	(8.5)	(29.2)	(26.1)
Total unallocated costs	[1]	(32.8)	(17.1)	(72.9)	(43.9)
Softgel Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		209.9	185.1	598.2	550.2
Segment EBITDA		51.4	35.4	125.3	104.8
Drug Delivery Solutions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		234.6	190.5	639.9	568.2
Segment EBITDA		59.5	39.9	151.5	139.5
Clinical Supply Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		97.5	71.5	249.5	226.0
Segment EBITDA		$ 15.7	$ 12.1	$ 37.8	$ 39.5

[1] Unallocated costs includes equity-based compensation, certain acquisition-related costs, impairment charges, certain other corporate directed costs, certain customer claim expenses related to the Beinheim facility suspension and other costs that are not allocated to the segments as follows:

[2] Segment results do not include restructuring and other costs associated with certain customer claim expenses related to the Beinheim facility suspension and certain acquisition-related costs.

[3] Amounts primarily relate to foreign currency translation gains and losses during all periods presented.